GILD Stock Analysis — Gilead Sciences
Sector: Healthcare
AI Verdict
Gilead trades cheap for the growth you're getting at 14.7x forward earnings with nearly 20% EPS growth expected, and the antiviral franchise moat makes those estimates more credible than most.
Competitive Moat
Gilead Sciences dominates in antiviral therapies, especially with its entrenched HIV and hepatitis franchises that benefit from years of clinical data and regulatory approvals. The high switching costs for physicians and payers, plus a robust patent portfolio, make its position defensible against generic competition.
Summary
Gilead is notable right now for trading at just 14.7x next year's earnings while analysts expect nearly 20% EPS growth.
Where It Stands
Gilead has returned 21.84% over the past year, its RSI of 51.4 signals a neutral setup, and its 14.7x forward P/E is well below the healthcare sector median of 22x.
Key Metrics
- RSI: 51.4 — Neutral
- Trailing P/E: 17.6x
- Forward P/E: 14.7x
- PEG Ratio: 0.88
- Earnings Growth: +0.2%
- Revenue Growth: +0.0%
- Market Cap: $159.6B
- Dividend Yield: 0.03%
- 1-Year Return: 21.84%
- 52-Week High: $157.29
- 52-Week Low: $100.23
Analyst Consensus
31 Buy · 8 Hold · 0 Sell (39 analysts)
Bull Case
With forward EPS growth projected at 19.7% and a forward P/E of 14.7x, you're paying a low price for above-average growth if Gilead's antiviral moat holds.
Bear Case
If the forward P/E reverts to the sector median of 22x only because earnings disappoint, the stock could see little upside despite recent 21.84% gains.
Catalyst to Watch
Watch for clinical trial readouts or regulatory decisions on pipeline drugs, as a negative outcome could quickly erase the current valuation discount.